Investigation of L-myc (T3109G) gene polymorphism in predicting of toxic complications risk in non-hodgkin's lymphomas treatment

Authors

  • Абушанаб А. А. Салах Shupik National Medical Academy of Postgraduate Education 9 Dorohozhytska str., Kyiv, Ukraine, 04112, Ukraine https://orcid.org/0000-0002-7342-1098
  • Станислав Владимирович Выдыборец Shupik National Medical Academy of Postgraduate Education 9 Dorohozhytska str., Kyiv, Ukraine, 04112, Ukraine https://orcid.org/0000-0003-0546-4325
  • Наталия Григорьевна Горовенко Shupik National Medical Academy of Postgraduate Education 9 Dorohozhytska str., Kyiv, Ukraine, 04112, Ukraine https://orcid.org/0000-0003-4227-7166
  • Ирина Радомировна Гартовская Shupik National Medical Academy of Postgraduate Education 9 Dorohozhytska str., Kyiv, Ukraine, 04112, Ukraine
  • Светлана Петровна Кирьяченко Shupik National Medical Academy of Postgraduate Education 9 Dorohozhytska str., Kyiv, Ukraine, 04112, Ukraine https://orcid.org/0000-0001-5782-0489
  • Зоя Ивановна Россоха SI «Reference-centre for molecular diagnostic of Public Health Ministry of Ukraine» 9 Dorohozhytska str., Kyiv, Ukraine, 04112, Ukraine https://orcid.org/0000-0002-4767-7364

DOI:

https://doi.org/10.15587/2519-4798.2016.70148

Keywords:

non-hodgkin’s lymphomas, chemotherapy toxicity, L-myc (T3109G) gene polymorphism

Abstract

Aim of research. To define the influence of polymorphic variants of L-myc (T3109G) gene on the risk of development of hematological and non-hematological toxicity at polychemotharapy in patients with the different forms of non-hodgkin’s lymphomas.

Methods. Patients with diffuse-macrocellular and microcellular lymphomas underwent 4 courses of polychemotherapy according to the nosologic forms of disease and treatment protocol. The clinical course of disease was assessed paying attention to the toxic effects and response on the therapy. The clinical-laboratory parameters in the period of disease manifestation were analyzed in details. All patients underwent the molecular-genetic examination of polymorphic variants of L-myc (T3109G) gene. Using the statistical analysis was assessed the influence of polymorphic variants of gene on the risk of development of toxic effects and the interconnection with clinic-laboratory parameters..

Results. The studies of the influence of polymorphic variants of L-myc (T3109G) gene on the risk of development of hematological and non-hematological toxicity at PCT at the different forms of NHL proved that the summary frequency of detection of the clinical cases of hematological and non-hematological toxicity did not differ in patients with DMCL and MCL and was not associated with polymorphism of the studied gene. Polymorphism of L-myc (T3109G) gene determined the spread of the tumor process, the risk of development of II-IV stages of disease that were detected more frequently at 3109ТG and 3109GG genotypes; and the 3109GG genotype was associated with the loss of body weight and the rise of the number of erythrocytes in the period of disease manifestation before the beginning of PCT courses. The risk of development of nephrological toxicity at chemotherapy in patients with NHL was associated with 3109ТG and 3109GG genotypes on L-myc gene. The number of toxic effects and the features of their combination in examined patients were not connected with polymorphism of L-myc (T3109G) gene.

Conclusions. The further studies are needed for elaboration of the therapeutic-preventive arrangements on the decrease of risk of nephrological toxicity in patients with non-hodgkin’s lymphomas at polychemotherapy courses

Author Biographies

Абушанаб А. А. Салах, Shupik National Medical Academy of Postgraduate Education 9 Dorohozhytska str., Kyiv, Ukraine, 04112

Postgraduate student

Department of hematology and transfusion

Станислав Владимирович Выдыборец, Shupik National Medical Academy of Postgraduate Education 9 Dorohozhytska str., Kyiv, Ukraine, 04112

MD, Professor

Department of hematology and transfusion

Наталия Григорьевна Горовенко, Shupik National Medical Academy of Postgraduate Education 9 Dorohozhytska str., Kyiv, Ukraine, 04112

MD, Professor, Corresponding Member of AMS of Ukraine

Department of medical genetics and laboratory

Ирина Радомировна Гартовская, Shupik National Medical Academy of Postgraduate Education 9 Dorohozhytska str., Kyiv, Ukraine, 04112

Candidate of medical sciences, Associate professor

Department of hematology and transfusion

Светлана Петровна Кирьяченко, Shupik National Medical Academy of Postgraduate Education 9 Dorohozhytska str., Kyiv, Ukraine, 04112

Candidate of biological sciences

Central Scientific Research Laboratory

Зоя Ивановна Россоха, SI «Reference-centre for molecular diagnostic of Public Health Ministry of Ukraine» 9 Dorohozhytska str., Kyiv, Ukraine, 04112

Candidate of medical sciences

References

  1. Tansey, W. P. (2014). Mammalian MYC Proteins and Cancer. New Journal of Science, 2014, 1–27. doi: 10.1155/2014/757534
  2. DePinho, R. A., Hatton, K. S., Tesfaye, A., Yancopoulos, G. D., Alt, F. W. (1987). The human myc gene family: structure and activity of L-myc and an L-myc pseudogene. Genes & Development, 1 (10), 1311–1326. doi: 10.1101/gad.1.10.1311
  3. Spinola, M. (2004). Meta-Analysis Suggests Association of L-myc EcoRI Polymorphism with Cancer Prognosis. Clinical Cancer Research, 10 (14), 4769–4775. doi: 10.1158/1078-0432.ccr-04-0055
  4. Wasylishen, A. R., Stojanova, A., Oliveri, S., Rust, A. C., Schimmer, A. D., Penn, L. Z. (2011). New model systems provide insights into Myc-induced transformation. Oncogene, 30 (34), 3727–3734. doi: 10.1038/onc.2011.88
  5. Dang, C. V. (2011). Therapeutic Targeting of Myc-Reprogrammed Cancer Cell Metabolism. Cold Spring Harbor Symposia on Quantitative Biology, 76 (0), 369–374. doi: 10.1101/sqb.2011.76.011296
  6. Wiese, K. E., Walz, S., von Eyss, B., Wolf, E., Athineos, D., Sansom, O., Eilers, M. (2013). The Role of MIZ-1 in MYC-Dependent Tumorigenesis. Cold Spring Harbor Perspectives in Medicine, 3 (12), a014290–a014290. doi: 10.1101/cshperspect.a014290
  7. Cherenkov, V. T., Petrov, A. B., Vasileva, T. M., Strozhenkov, M. M. (2013). Vozmozhnosti «REMAKSOLA» dlya profilaktiki toksicheskih gepatitov pri himioterapii onkologicheskih bolnyih [Features "remaxol" for the prevention of toxic hepatitis during chemotherapy cancer patients]. Voprosyi onkologii, 59 (3). Available at: http://medi.ru/doc/a210421.htm [in Russia]
  8. Sharma, R., Cunningham, D., Smith, P., Robertson, G., Dent, O., Clarke, S. J. (2009). Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer, 9 (1), 153. doi: 10.1186/1471-2407-9-153
  9. Xu, X., Zhang, Y., Wang, Z., Wu, X., Yu, Y., Yan, B. (2013). Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy. OncoTargets and Therapy, 1385. doi: 10.2147/ott.s47764
  10. Dotan, E., Aggarwal, C., Smith, M. (2010). Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin’s Lymphoma. PT, 35 (3), 148–157.
  11. Rossini, F., Terruzzi, E., Perego, D., Miccolis, I., Rivolta, F., Manca, E., Pogliani, E. M. (2004). Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone. Cancer, 100 (2), 350–355. doi: 10.1002/cncr.11907
  12. Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M. (2016). NCCN Clinical Practice Guidelines in oncology. Journal of the National Comprehensive Cancer Network, 14 (5), 574–597.
  13. Wunderlich, A. (2003). Practicability and acute hematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Annals of Oncology, 14 (6), 881–893. doi: 10.1093/annonc/mdg249
  14. McCloskey, J. K., Broome, C. M., Cheson, B. D. (2013). Safe and Effective Treatment of Aggressive Non-Hodgkin Lymphoma With Rituximab and Bendamustine in Patients With Severe Liver Impairment. Clinical Advances Hematology Oncology, 11 (3), 184–189.
  15. Nastoupil, L. J., Sinha, R., Flowers, C. R. (2012). Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma. Oncology & Hematology Review (US), 08 (01), 71. doi: 10.17925/ohr.2012.08.1.71
  16. Overdevest, J. B., Theodorescu, D., Lee, J. K. (2009). Utilizing the Molecular Gateway: The Path to Personalized Cancer Management. Clinical Chemistry, 55 (4), 684–697. doi: 10.1373/clinchem.2008.118554
  17. Human Gene Data Base. Available at: http://www.genecards.org/cgi-bin/carddisp.pl?gene=MYCL
  18. Tilly, H., Vitolo, U., Walewski, J., da Silva, M. G., Shpilberg, O., Andre, M. et. al (2012). Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23, vii78–vii82. doi: 10.1093/annonc/mds273
  19. Stewart, D. (2013). Non-Hodgkin lymphoma. Landmarks, 12 (1), 43–45.
  20. Abushanab, S., Vydyborec, S. V., Gorovenko, N. G., Gartovskaya, I. P., Kyriachenko, S. P., Rossokha, Z. I. (2015). Vliyanie geneticheskih faktorov na razvitie razlichnyh klinicheskih proyavlenij toksichnosti u bol'nyh nehodzhkinskimi limfomami. [Influence of genetic factors on the development of different clinical manifestations of toxicity in patients with non-Hodgkin's lymphomas]. Hematology Transfusiology. Eastern Europe, 3, 48–61.
  21. Yaylim-Eraltan, I., Bozkurt, N., Ergen, A., Zeybek, U. et. al (2008). L-myc gene polymorphism and risk of thyroid cancer. Experimental Oncology, 30 (2), 117–120.
  22. Common Terminology Criteria for Adverse Events (CTCAE). Available at: https://www.eortc.be/services/doc/ctc
  23. Alekseeva, Yu. A. (2013). Sovremennaya terapiya nehodzhkinskih limfom [Modern therapy Non-Hodgkin Lymphoma]. Farmateka, 8, 23–29.
  24. Dzhalilov, A. F. (2013). Nehodzhkinskie limfomyi: osnovyi klassifikatsii i osnovyi klassifikatsii i immunotsitohimicheskoy diagnostiki [Non-Hodgkin's lymphoma: a basis of classification and the basis of classification and immunocytochemical diagnosis]. Onkologiya, 15 (4), 264–272.

Downloads

Published

2016-05-31

How to Cite

Салах, А. . А. А., Выдыборец, С. В., Горовенко, Н. Г., Гартовская, И. Р., Кирьяченко, С. П., & Россоха, З. И. (2016). Investigation of L-myc (T3109G) gene polymorphism in predicting of toxic complications risk in non-hodgkin’s lymphomas treatment. ScienceRise: Medical Science, (5 (1), 36–44. https://doi.org/10.15587/2519-4798.2016.70148

Issue

No. 5 (1) (2016)

Section

Medical Science

License

Copyright (c) 2016 Абушанаб А. А. Салах, Станислав Владимирович Выдыборец, Наталия Григорьевна Горовенко, Ирина Радомировна Гартовская, Светлана Петровна Кирьяченко, Зоя Ивановна Россоха

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.